FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W76243008> ?p ?o ?g. }

• W76243008 endingPage "5447" @default.
• W76243008 startingPage "5447" @default.
• W76243008 abstract "Abstract Background: Diffuse Large B Cell Lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, and is frequently diagnosed in elderly patients. Elderly patients with DLBCL are known to have worse outcomes than younger patients with the same disease, in part due to comorbidities and poor performance status that may decrease their ability to tolerate treatment. A recent phase II study (Lancet Oncology 2011;12:460-8) demonstrated that patients with DLBCL who were older than 80 years of age had excellent tolerability while still maintaining efficacy when treated with an attenuated dose of R-CHOP called “R-mini-CHOP”. This paper prompted a change in treatment policy of very elderly patients with DLBCL at the London Regional Cancer Program. In November 2011, we began treating all DLBCL patients > 80 (and select patients aged 70-79 with significant comorbidities) with the R-mini-CHOP regimen rather than with standard R-CHOP or a ‘randomly dose-attenuated version’ of R-CHOP, which had been our practice prior to the policy change. Objective: This quality assurance study was undertaken in order to monitor and ensure the safety and efficacy of this practice change. Methods: Data was collected prospectively on all elderly patients with DLBCL who were initiated on R-mini-CHOP between November 2011 and January 2013. A retrospective chart review was also performed on patients > 80 treated at our centre in the preceding 10 years, after R-CHOP became standard treatment in elderly patients with DLBCL. We used 16 patients > 80 who received full dose R-CHOP between January 2010 and November 2011 as a historical control group for our prospective cohort. Results: Since November 2011, 17 patients (median age 81, range 71-90) have been treated with R-mini-CHOP and were enrolled in this quality assurance study. All 17 patients had stage III or IV disease. In contrast, only 6/16 patients in the retrospective group were advanced stage (p=0.00004). 12/17 R-mini-CHOP patients (70.6%) had an ECOG > 1, vs. 7/16 R-CHOP patients (43.8%, p=0.070). No dose modifications have been required in patients on R-mini-CHOP. 11/16 patients on R-CHOP underwent dose reductions due to side effects of chemotherapy. The majority of patients in both cohorts received primary prophylaxis with neupogen/neulasta. Five patients remain on R-mini-CHOP, all showing evidence of clinical response. Follow-up is too short to report on PFS or OS, but overall response rate thus far is 10/12 (83%) with 7 CRs (58.3%) and 3 PRs (25%). This compares favorably to the retrospective group who had an ORR of 13/16 (81%, p=0.30), 7 CRs (43.8%) and 6 PR’s (37.5%). One patient in each group had stable disease at the end of treatment. One mini-R-CHOP patient progressed on treatment and ultimately died of lymphoma. In the retrospective cohort, 4 deaths occurred secondary to infectious complications of chemotherapy during treatment period. C onclusions: Results with R-mini-CHOP have been encouraging so far. Despite the more aggressive disease (higher stage, inferior ECOG) in our R-mini-CHOP patients compared to the historical controls treated with R-CHOP, similar response rates are being achieved, with fewer adverse effects and better tolerability. Ongoing enrollment and longer follow-up will further help define the role of R-mini-CHOP in the very elderly patient population. Updated results with longer followup will be presented at the meeting. Disclosures No relevant conflicts of interest to declare." @default.
• W76243008 created "2016-06-24" @default.
• W76243008 creator A5032169935 @default.
• W76243008 creator A5056868786 @default.
• W76243008 creator A5065471848 @default.
• W76243008 creator A5082823626 @default.
• W76243008 date "2014-12-06" @default.
• W76243008 modified "2023-09-27" @default.
• W76243008 title "Safety and Efficacy of Dose Attentuated R-CHOP Chemotherapy for Treatment of Diffuse Large B Cell Lymphoma in the Very Elderly: A Cohort Study" @default.
• W76243008 doi "https://doi.org/10.1182/blood.v124.21.5447.5447" @default.
• W76243008 hasPublicationYear "2014" @default.
• W76243008 type Work @default.
• W76243008 sameAs 76243008 @default.
• W76243008 citedByCount "0" @default.
• W76243008 crossrefType "journal-article" @default.
• W76243008 hasAuthorship W76243008A5032169935 @default.
• W76243008 hasAuthorship W76243008A5056868786 @default.
• W76243008 hasAuthorship W76243008A5065471848 @default.
• W76243008 hasAuthorship W76243008A5082823626 @default.
• W76243008 hasConcept C121608353 @default.
• W76243008 hasConcept C126322002 @default.
• W76243008 hasConcept C143998085 @default.
• W76243008 hasConcept C197934379 @default.
• W76243008 hasConcept C2778336483 @default.
• W76243008 hasConcept C2778375690 @default.
• W76243008 hasConcept C2778559949 @default.
• W76243008 hasConcept C2779338263 @default.
• W76243008 hasConcept C2779725641 @default.
• W76243008 hasConcept C2781413609 @default.
• W76243008 hasConcept C71924100 @default.
• W76243008 hasConceptScore W76243008C121608353 @default.
• W76243008 hasConceptScore W76243008C126322002 @default.
• W76243008 hasConceptScore W76243008C143998085 @default.
• W76243008 hasConceptScore W76243008C197934379 @default.
• W76243008 hasConceptScore W76243008C2778336483 @default.
• W76243008 hasConceptScore W76243008C2778375690 @default.
• W76243008 hasConceptScore W76243008C2778559949 @default.
• W76243008 hasConceptScore W76243008C2779338263 @default.
• W76243008 hasConceptScore W76243008C2779725641 @default.
• W76243008 hasConceptScore W76243008C2781413609 @default.
• W76243008 hasConceptScore W76243008C71924100 @default.
• W76243008 hasIssue "21" @default.
• W76243008 hasLocation W762430081 @default.
• W76243008 hasOpenAccess W76243008 @default.
• W76243008 hasPrimaryLocation W762430081 @default.
• W76243008 hasRelatedWork W1989464859 @default.
• W76243008 hasRelatedWork W2007833599 @default.
• W76243008 hasRelatedWork W2034116266 @default.
• W76243008 hasRelatedWork W2247122458 @default.
• W76243008 hasRelatedWork W2558349019 @default.
• W76243008 hasRelatedWork W2588498504 @default.
• W76243008 hasRelatedWork W2778538208 @default.
• W76243008 hasRelatedWork W2978307598 @default.
• W76243008 hasRelatedWork W2979864420 @default.
• W76243008 hasRelatedWork W3204790564 @default.
• W76243008 hasVolume "124" @default.
• W76243008 isParatext "false" @default.
• W76243008 isRetracted "false" @default.
• W76243008 magId "76243008" @default.
• W76243008 workType "article" @default.